Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2022 Earnings Call Transcript

Panna Sharma: And just to add on to that, we will be doing liquid biopsy at enrollment and multiple time points wherever possible in all of our trials. So it’ll be pretty standard. So we’ll do them in the GBM trial, we’ll be doing it on the solid tumor trial for 184, we’ll be doing it on the 284 trial, because it just — there’s a wealth of data, the costs for liquid biopsy have gotten much more reasonable. And if patients are amenable to it, in which many cases they are, it gives us a lot of very clear ideas of how to advance the molecule.

Nicole Leber: That is all the questions I see that we have for today. So thank you, everyone, for joining and have a great rest of your day.

Panna Sharma: Nicole, thank you. David thanks.

David Margrave: Thanks a lot. I appreciate it. Bye-bye.